Literature DB >> 7841052

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.

G Scambia1, U Testa, P Benedetti Panici, E Foti, R Martucci, A Gadducci, A Perillo, V Facchini, C Peschle, S Mancuso.   

Abstract

High levels of IL-6 were found in 50% of 114 patients with primary ovarian cancer. IL-6 sensitivity was lower than that of CA 125, and the combination of both assays did not increase the sensitivity of CA 125 alone. However, elevated IL-6 serum levels were correlated with a poor prognosis since patients with low IL-6 levels had a better survival than patients with high IL-6 levels (P = 0.0009). Multivariate analysis revealed that IL-6 positivity has an independent value.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7841052      PMCID： PMC2033591          DOI： 10.1038/bjc.1995.71

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  16 in total

1.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

Authors:  J Y Blay; S Negrier; V Combaret; S Attali; E Goillot; Y Merrouche; A Mercatello; A Ravault; J M Tourani; J F Moskovtchenko
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

2.  Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.

Authors:  S Wu; K Rodabaugh; O Martinez-Maza; J M Watson; D S Silberstein; C M Boyer; W P Peters; J B Weinberg; J S Berek; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1992-03       Impact factor: 8.661

3.  Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.

Authors:  J S Berek; C Chung; K Kaldi; J M Watson; R M Knox; O Martínez-Maza
Journal:  Am J Obstet Gynecol       Date:  1991-04       Impact factor: 8.661

4.  Human glioblastoma cells release interleukin 6 in vivo and in vitro.

Authors:  E Van Meir; Y Sawamura; A C Diserens; M F Hamou; N de Tribolet
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

5.  Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up.

Authors:  P. Benedetti Panici; S. Greggi; G. Scambia; G. Baiocchi; M. Lomonaco; G. Conti; S. Mancuso
Journal:  Int J Gynecol Cancer       Date:  1993-01       Impact factor: 3.437

6.  Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.

Authors:  B Motro; A Itin; L Sachs; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.

Authors:  M Honda; S Yamamoto; M Cheng; K Yasukawa; H Suzuki; T Saito; Y Osugi; T Tokunaga; T Kishimoto
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

8.  Interleukin-6 serum levels in patients with gynecological tumors.

Authors:  G Scambia; U Testa; P B Panici; R Martucci; E Foti; M Petrini; M Amoroso; V Masciullo; C Peschle; S Mancuso
Journal:  Int J Cancer       Date:  1994-05-01       Impact factor: 7.396

9.  Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells.

Authors:  I Tamm; I Cardinale; J Krueger; J S Murphy; L T May; P B Sehgal
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

10.  Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.

Authors:  G Scambia; P Benedetti Panici; L Perrone; C Sonsini; S Giannelli; A Gallo; P G Natali; S Mancuso
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640
View more
  55 in total

1.  A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.

Authors:  Joong-Jae Lee; Hyun Jung Kim; Chul-Su Yang; Hyun-Ho Kyeong; Jung-Min Choi; Da-Eun Hwang; Jae-Min Yuk; Keunwan Park; Yu Jung Kim; Seung-Goo Lee; Dongsup Kim; Eun-Kyeong Jo; Hae-Kap Cheong; Hak-Sung Kim
Journal:  Mol Ther       Date:  2014-03-31       Impact factor: 11.454

Review 2.  Biobehavioral influences on cancer progression.

Authors:  Erin S Costanzo; Anil K Sood; Susan K Lutgendorf
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

3.  Interleukin-6 and body mass index, tobacco use, and sleep in gynecologic cancers.

Authors:  Elizabeth L Kacel; Janae L Kirsch; Timothy S Sannes; Seema Patidar; Rachel Postupack; Sally Jensen; Shan Wong; Stephanie Garey; Stacy Dodd; Chantel M Ulfig; Christina S McCrae; Michael E Robinson; Jacqueline Castagno; Gregory S Schultz; Deidre B Pereira
Journal:  Health Psychol       Date:  2019-08-01       Impact factor: 4.267

4.  Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells.

Authors:  Premkumar Vummidi Giridhar; Holly M Funk; Catherine A Gallo; Aleksey Porollo; Carol A Mercer; David R Plas; Angela F Drew
Journal:  Clin Exp Metastasis       Date:  2011-09-02       Impact factor: 5.150

5.  Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer.

Authors:  Wei Chua; Stephen J Clarke; Kellie A Charles
Journal:  Support Care Cancer       Date:  2011-10-11       Impact factor: 3.603

6.  Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.

Authors:  Wei Wen; Wei Liang; Jun Wu; Claudia M Kowolik; Ralf Buettner; Anna Scuto; Meng-Yin Hsieh; Hao Hong; Christine E Brown; Stephen J Forman; David Horne; Robert Morgan; Mark Wakabayashi; Thanh H Dellinger; Ernest S Han; John H Yim; Richard Jove
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

7.  Plasma immune analytes in patients with epithelial ovarian cancer.

Authors:  Matthew S Block; Matthew J Maurer; Krista Goergen; Kimberly R Kalli; Courtney L Erskine; Marshall D Behrens; Ann L Oberg; Keith L Knutson
Journal:  Cytokine       Date:  2015-03-03       Impact factor: 3.861

8.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

9.  Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.

Authors:  Susan K Lutgendorf; Premal H Thaker; Jesusa M Arevalo; Michael J Goodheart; George M Slavich; Anil K Sood; Steve W Cole
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

10.  Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.

Authors:  Munehiro Yoshitomi; Shigeru Yutani; Satoko Matsueda; Tetsuya Ioji; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh; Tetsuro Sasada; Hisafumi Kinoshita
Journal:  Exp Ther Med       Date:  2011-12-20       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.